| Literature DB >> 30878505 |
Sara Rodríguez-Enríquez1, Silvia Cecilia Pacheco-Velázquez2, Álvaro Marín-Hernández2, Juan Carlos Gallardo-Pérez2, Diana Xochiquetzal Robledo-Cadena2, Ileana Hernández-Reséndiz2, Jorge Donato García-García2, Javier Belmont-Díaz2, Rebeca López-Marure3, Luz Hernández-Esquivel2, Rosina Sánchez-Thomas2, Rafael Moreno-Sánchez4.
Abstract
The resveratrol (RSV) efficacy to affect the proliferation of several cancer cell lines was initially examined. RSV showed higher potency to decrease growth of metastatic HeLa and MDA-MB-231 (IC50 = 200-250 μM) cells than of low metastatic MCF-7, SiHa and A549 (IC50 = 400-500 μM) and non-cancer HUVEC and 3T3 (IC50≥600 μM) cells after 48 h exposure. In order to elucidate the biochemical mechanisms underlying RSV anti-cancer effects, the energy metabolic pathways and the oxidative stress metabolism were analyzed in HeLa cells as metastatic-type cell model. RSV (200 μM/48 h) significantly decreased both glycolysis and oxidative phosphorylation (OxPhos) protein contents (30-90%) and fluxes (40-70%) vs. non-treated cells. RSV (100 μM/1-5 min) also decreased at a greater extent OxPhos flux (net ADP-stimulated respiration) of isolated tumor mitochondria (> 50%) than of non-tumor mitochondria (< 50%), particularly with succinate as oxidizable substrate. In addition, RSV promoted an excessive cellular ROS (2-3 times) production corresponding with a significant decrement in the SOD activity (but not in its content) and GSH levels; whereas the catalase, glutahione reductase, glutathione peroxidase and glutathione-S-transferase activities (but not their contents) remained unchanged. RSV (200 μM/48 h) also induced cellular death although not by apoptosis but rather by promoting a strong mitophagy activation (65%). In conclusion, RSV impaired OxPhos by inducing mitophagy and ROS over-production, which in turn halted metastatic HeLa cancer cell growth.Entities:
Keywords: Antioxidant response; Cancer; Mitophagy; Oxidative phosphorylation; ROS production
Mesh:
Substances:
Year: 2019 PMID: 30878505 DOI: 10.1016/j.taap.2019.03.008
Source DB: PubMed Journal: Toxicol Appl Pharmacol ISSN: 0041-008X Impact factor: 4.219